benserazide has been researched along with Hyperhomocysteinemia in 2 studies
Benserazide: An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
benserazide : A carbohydrazide that results from the formal condensation of the carboxy group of DL-serine with the primary amino group of 4-(hydrazinylmethyl)benzene-1,2,3-triol. An aromatic-L-amino-acid decarboxylase inhibitor (DOPA decarboxylase inhibitor) that does not enter the central nervous system, it is used as its hydrochloride salt as an adjunct to levodopa in the treatment of parkinsonism. By preventing the conversion of levodopa to dopamine in the periphery, it causes an increase in the amount of levodopa reaching the central nervous system and so reduces the required dose. Benserazide has no antiparkinson actions when given alone.
Hyperhomocysteinemia: Condition in which the plasma levels of homocysteine and related metabolites are elevated (
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aims to investigate hyperhomocysteinemia (HHcy) resulted from treatment in patients with Parkinson's disease (PD) and to evaluate the therapeutic outcome of HHcy." | 7.83 | The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia. ( Cao, LD; Guo, G; Wu, QY; Xu, S, 2016) |
| "This study aims to investigate hyperhomocysteinemia (HHcy) resulted from treatment in patients with Parkinson's disease (PD) and to evaluate the therapeutic outcome of HHcy." | 3.83 | The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia. ( Cao, LD; Guo, G; Wu, QY; Xu, S, 2016) |
| " The present results show beneficial antioxidant and methyl donor properties of betaine versus oxidative stress and hyperhomocysteinemia induced by levodopa and benserazide in an animal model." | 3.81 | Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats. ( Alirezaei, M; Dezfoulian, O; Khoshdel, Z; Rashidipour, M; Taghadosi, V, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alirezaei, M | 1 |
| Khoshdel, Z | 1 |
| Dezfoulian, O | 1 |
| Rashidipour, M | 1 |
| Taghadosi, V | 1 |
| Guo, G | 1 |
| Xu, S | 1 |
| Cao, LD | 1 |
| Wu, QY | 1 |
2 other studies available for benserazide and Hyperhomocysteinemia
| Article | Year |
|---|---|
Beneficial antioxidant properties of betaine against oxidative stress mediated by levodopa/benserazide in the brain of rats.
Topics: Animals; Antioxidants; Benserazide; Betaine; Brain; Dopamine; Dopamine Agents; Drug Combinations; Gl | 2015 |
The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Topics: Antiparkinson Agents; Benserazide; Dopamine Agents; Drug Combinations; Homocysteine; Humans; Hyperho | 2016 |